October 18, 2019 / 5:20 AM / 25 days ago

BRIEF-Roche Holding: FDA Approval For Xofluza

Oct 18 (Reuters) - Roche Holding Ag:

* ROCHE ANNOUNCES FDA APPROVAL OF XOFLUZA (BALOXAVIR MARBOXIL) FOR PEOPLE AT HIGH RISK OF DEVELOPING INFLUENZA-RELATED COMPLICATIONS

* XOFLUZA IS THE FIRST AND ONLY ANTIVIRAL MEDICINE INDICATED SPECIFICALLY FOR PATIENTS AT HIGH RISK OF DEVELOPING SERIOUS COMPLICATIONS FROM INFLUENZA Source text: [bit.ly/2P3OKDM] Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below